Dr. Chet R. Villa of Cincinnati Children's Hospital Medical Center detailed how the 12-month FIGHT DMD trial demonstrated a 5.4% improvement in left ventricular ejection fraction compared to control groups. Beyond these functional gains, new 36-month data from an open-label extension highlight favorable safety profiles and specific biological markers of tissue repair. Patients treated with ifetroban showed a 30% reduction in MYL3 and a 50% reduction in MYOD1, both of which are circulating indicators of heart muscle damage.

These results address a significant gap in pediatric care, as no FDA-approved therapies currently target the underlying cardiac complications inherent to Duchenne muscular dystrophy. Cumberland Pharmaceuticals plans to continue long-term treatment analyses and supportive studies to further validate ifetroban’s efficacy. Pat Furlong, CEO of Parent Project Muscular Dystrophy, noted that the data provide a promising path toward a specialized treatment for families navigating the universal cardiac risks of the disease.